Stock Market Today, March 9: Hims & Hers Health Soars on Novo Nordisk Weight-Loss Drug Deal

Hims & Hers stock surged 40.72% to $22.15 after agreeing a deal with Novo Nordisk that ends a patent infringement suit and allows Hims to sell Novo’s branded GLP-1 Ozempic while ceasing marketing of compounded GLP‑1s. Trading volume spiked to 168.1M shares (~557% above its 3‑month average), Needham and Citi raised price targets to $30 and $24, and the stock now trades at about 20x forward earnings—removing a major legal headwind despite being down ~62% from its 52‑week high.

Analysis

The strategic pivot from bespoke compound scripts to an upstream branded supply model is a classic margin/volume trade-off: per-script economics will likely compress, but customer acquisition and retention should materially improve if fulfillment becomes frictionless and insured coverage follows. Expect LTV uplift to appear within 6–12 months as prescription continuity and cross-sell (sexual health, mental health subscriptions) reduce CAC payback by an estimated 20–40%, assuming retention improves modestly.

Second-order winners include national wholesalers and specialty distributors who will pick up volume lost by compounding pharmacies; regional compounding players are the obvious losers and an early place to look for dispersion. Competing telehealth platforms face a fork: partner with branded manufacturers (lower gross per script, more scale) or double down on niche compounded offerings and accept ongoing litigation and regulatory friction.

Key risks are concentration and gross‑to‑net compression: reliance on a single large supplier gives the partner pricing leverage and operational vetoes (supply prioritization, co‑op marketing, formulary access), so a supply disruption or an unfavorable trade‑term reset could reverse margin gains fast. Monitor three near‑term readouts as reversal catalysts — realized ASP after rebates, percent of revenue from branded GLP‑1s, and churn among non‑GLP subscription customers — each can swing enterprise value by multiples within a 3–12 month window.

The market is likely re‑rating headline legal risk out of price but may be underpricing execution and counterparty risk; today’s rerating creates room for tactical entry, but size for realizable operational improvement (scripts/pt, retention, gross margin) rather than purely multiple expansion.

Key Decisions for Investors

• Long HIMS equity (6–12 month horizon): initiate a 1–2% portfolio position to capture re‑rating as operational metrics normalize. Target asymmetric upside of 40–80% if retention + ASP stabilize; cap downside risk by sizing to a maximum 20% drawdown on the position.
• Call‑spread on HIMS (9–12 months): buy a moderately OTM long call and sell a higher strike to finance cost (3:1 upside skew). This expresses a directional view while limiting premium decay; allocate no more than 0.5% of risk budget, break‑even contingent on 30–50% move in implied forward EV/EBITDA multiple.
• Pair trade – Long HIMS / Short AMWL or short less differentiated telehealth name (3–6 months): go net market‑neutral to exploit expected share gains in weighted medication scripts. Size the short to offset ~60–80% of HIMS beta; profit if HIMS gains share on GLP‑1 funnels while the peer fails to monetize branded flow.
• Downside protection: if taking a larger HIMS position, buy a 3–6 month protective put or construct a collar (sell out‑of‑the‑money calls). This hedges single‑supplier and formulary risks that could materialize quickly and compress valuation by >30% in a supply shock scenario.